Skip to main content
SpringerLink
Log in

Dyslipidemia in the Kidney Transplant Patient

  • Chapter
  • First Online:
Dyslipidemias in Kidney Disease

  • 742 Accesses

Abstract

Premature cardiovascular death remains one of the commonest causes of morbidity and mortality in renal transplant recipients (RTRs), and there is a significant association between dyslipidemia and cardiovascular disease. Abnormalities include elevation of total cholesterol, triglyceride, and low-density lipoprotein fractions and are due to multiple factors, including immunosuppressant therapy, patient characteristics, and preexisting comorbidities. Evidence suggests that reducing these lipid abnormalities may provide significant cardiovascular benefit to RTRs and, as a result, modification is recommended. Pharmacological intervention with statin therapy is recommended based on results from the ALERT study, although there is a reluctance to prescribe these agents in transplant recipients due to risk of side effects and drug interactions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341(23):1725–30.

    Article  PubMed  CAS  Google Scholar 

  2. Meier-Kriesche HU, Schold JD, Srinivas TR, Reed A, Kaplan B. Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease. Am J Transplant. 2004;4(10):1662–8.

    Article  PubMed  Google Scholar 

  3. Nankivell BJ, Alexander SI. Rejection of the kidney allograft. N Engl J Med. 2010;363(15): 1451–62.

    Article  PubMed  CAS  Google Scholar 

  4. USRDS 2012 Annual Data Report. 2013. www.usrds.org

  5. Jardine AG, Gaston RS, Fellstrom BC, Holdaas H. Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet. 2011;378(9800):1419–27.

    Article  PubMed  Google Scholar 

  6. Moore R, Thomas D, Morgan E, Wheeler D, Griffin P, Salaman J, et al. Abnormal lipid and lipoprotein profiles following renal transplantation. Transplant Proc. 1993;25(1 Pt 2):1060–1.

    PubMed  CAS  Google Scholar 

  7. Vanrenterghem Y, Lebranchu Y, Hene R, Oppenheimer F, Ekberg H. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation. 2000;70(9):1352–9.

    Article  PubMed  CAS  Google Scholar 

  8. Kuster GM, Drexel H, Bleisch JA, Rentsch K, Pei P, Binswanger U, et al. Relation of cyclosporine blood levels to adverse effects on lipoproteins. Transplantation. 1994;57(10):1479–83.

    Article  PubMed  CAS  Google Scholar 

  9. Artz MA, Boots JM, Ligtenberg G, Roodnat JI, Christiaans MH, Vos PF, et al. Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus. J Am Soc Nephrol. 2003;14(7):1880–8.

    Article  PubMed  CAS  Google Scholar 

  10. Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357(25):2562–75.

    Article  PubMed  CAS  Google Scholar 

  11. Hoogeveen RC, Ballantyne CM, Pownall HJ, Opekun AR, Hachey DL, Jaffe JS, et al. Effect of sirolimus on the metabolism of apo. Transplantation. 2001;72(7):1244–50.

    Article  PubMed  CAS  Google Scholar 

  12. Schena FP, Pascoe MD, Alberu J, del Carmen RM, Oberbauer R, Brennan DC, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation. 2009;87(2): 233–42.

    Article  PubMed  CAS  Google Scholar 

  13. Renal Association. 2009. http://www.renal.org/

  14. Pilmore H, Dent H, Chang S, McDonald SP, Chadban SJ. Reduction in cardiovascular death after kidney transplantation. Transplantation. 2010;89(7):851–7.

    Article  PubMed  Google Scholar 

  15. Kasiske BL. Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med. 1988;84(6):985–92.

    Article  PubMed  CAS  Google Scholar 

  16. Vanrenterghem YF, Claes K, Montagnino G, Fieuws S, Maes B, Villa M, et al. Risk factors for cardiovascular events after successful renal transplantation. Transplantation. 2008;85(2):209–16.

    Article  PubMed  Google Scholar 

  17. Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003;361(9374):2024–31.

    Article  PubMed  CAS  Google Scholar 

  18. Holdaas H, Fellstrom B, Cole E, Nyberg G, Olsson AG, Pedersen TR, et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant. 2005;5(12):2929–36.

    Article  PubMed  CAS  Google Scholar 

  19. Ong CS, Pollock CA, Caterson RJ, Mahony JF, Waugh DA, Ibels LS. Hyperlipidemia in renal transplant recipients: natural history and response to treatment. Medicine (Baltimore). 1994;73(4):215–23.

    Article  CAS  Google Scholar 

  20. Ghods AJ, Milanian I, Arghani H, Ghadiri G. The efficacy and safety of fluvastatin in hypercholesterolemia in renal transplant recipients. Transplant Proc. 1995;27(5):2579–80.

    PubMed  CAS  Google Scholar 

  21. Navaneethan SD, Perkovic V, Johnson DW, Nigwekar SU, Craig JC, Strippoli GF. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database Syst Rev. 2009;2, CD005019.

    PubMed  Google Scholar 

  22. Puthenparumpil JJ, Keough-Ryan T, Kiberd M, Lawen J, Kiberd BA. Treatment of hypercholesterolemia with ezetimibe in the kidney transplant population. Transplant Proc. 2005;37(2): 1033–5.

    Article  PubMed  CAS  Google Scholar 

  23. Langone AJ, Chuang P. Ezetimibe in renal transplant patients with hyperlipidemia resistant to HMG-CoA reductase inhibitors. Transplantation. 2006;81(5):804–7.

    Article  PubMed  CAS  Google Scholar 

  24. Lal SM, Hewett JE, Petroski GF, Van Stone JC, Ross Jr G. Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labeled crossover trial. Am J Kidney Dis. 1995;25(4):616–22.

    Article  PubMed  CAS  Google Scholar 

  25. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301–7.

    Article  PubMed  CAS  Google Scholar 

  26. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383–9.

    Google Scholar 

  27. Cosio FG, Pesavento TE, Pelletier RP, Henry M, Ferguson RM, Kim S, et al. Patient survival after renal transplantation III: the effects of statins. Am J Kidney Dis. 2002;40(3):638–43.

    Article  PubMed  CAS  Google Scholar 

  28. Wiesbauer F, Heinze G, Mitterbauer C, Harnoncourt F, Horl WH, Oberbauer R. Statin use is associated with prolonged survival of renal transplant recipients. J Am Soc Nephrol. 2008;19(11):2211–8.

    Article  PubMed Central  PubMed  Google Scholar 

  29. Hausberg M, Kosch M, Stam F, Heidenreich S, Kisters K, Rahn KH, et al. Effect of fluvastatin on endothelium-dependent brachial artery vasodilation in patients after renal transplantation. Kidney Int. 2001;59(4):1473–9.

    Article  PubMed  CAS  Google Scholar 

  30. Seron D, Oppenheimer F, Pallardo LM, Lauzurica R, Errasti P, Gomez-Huertas E, et al. Fluvastatin in the prevention of renal transplant vasculopathy: results of a prospective, randomized, double-blind, placebo-controlled trial. Transplantation. 2008;86(1):82–7.

    Article  PubMed  CAS  Google Scholar 

  31. Holdaas H, Fellstrom B, Jardine AG, Nyberg G, Gronhagen-Riska C, Madsen S, et al. Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation. Nephrol Dial Transplant. 2005;20(5):974–80.

    Article  PubMed  CAS  Google Scholar 

  32. Holdaas H, Fellstrom B, Holme I, Nyberg G, Fauchald P, Jardine A, et al. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data. J Cardiovasc Risk. 2001;8(2):63–71.

    Article  PubMed  CAS  Google Scholar 

  33. Kasiske B, Cosio FG, Beto J, Bolton K, Chavers BM, Grimm Jr R, et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant. 2004;4 Suppl 7:13–53.

    Article  PubMed  Google Scholar 

  34. Asberg A, Hartmann A, Fjeldsa E, Bergan S, Holdaas H. Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am J Transplant. 2001;1(4):382–6.

    Article  PubMed  CAS  Google Scholar 

  35. Launay-Vacher V, Izzedine H, Deray G. Statins’ dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients. Int J Cardiol. 2005;101(1):9–17.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Renal Research Group, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK

    Rajan Kantilal Patel M.B.Ch.B., Ph.D.

  2. Institute of Cardiovascular and Medical Sciences, University of Glasgow, 129 University Place, Glasgow, G128TA, UK

    Alan G. Jardine Bs.C., M.D., F.E.S.C., F.E.B.S.

Authors
  1. Rajan Kantilal Patel M.B.Ch.B., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alan G. Jardine Bs.C., M.D., F.E.S.C., F.E.B.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alan G. Jardine Bs.C., M.D., F.E.S.C., F.E.B.S. .

Editor information

Editors and Affiliations

  1. "C.I. Parhon" University Hospital, City, Iasi, Romania

    Adrian Covic

  2. Department of Medicine, Istanbul Medeniyet University School of Medicine, Istanbul, Turkey

    Mehmet Kanbay

  3. Department of Medicine, University of Illinois at Chicago College of Medicine, Chicago, Illinois, USA

    Edgar V. Lerma

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Patel, R.K., Jardine, A.G. (2014). Dyslipidemia in the Kidney Transplant Patient. In: Covic, A., Kanbay, M., Lerma, E. (eds) Dyslipidemias in Kidney Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0515-7_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-0515-7_11

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-0514-0

  • Online ISBN: 978-1-4939-0515-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation